Updated on 02.04.2026|11:14 AM
Sai Parenteral's Limited is set to launch its Initial Public Offering (IPO). It is a diversified pharmaceutical formulations company with robust research, development, and manufacturing capabilities in both Branded Generics and Contract Development and Manufacturing Organisation (CDMO) services.
The public issue will open for subscription on Tuesday, March 24, 2026, and close on Friday, March 27, 2026. Track all the upcoming and live IPOs of 2026 at our IPO section which is updated regularly.
Through a combination of a Fresh Issue worth ₹285 Crores and an Offer for Sale (OFS) of up to 31,57,880 shares, the company aims to raise approximately ₹408.79 Crores at the upper price band to fund capacity expansion, a new R&D centre, and strategic debt repayment. Track
In this article, you will find Sai Parenteral's IPO GMP today, price band, and a detailed review with financial performance, strengths and risks, valuations and objectives. For allotment, you can check our IPO allotment page and for daywise subscription check our detailed daywise subscription section.
Briefs of Sai Parenteral's IPO Details:
- Price Band: ₹372 – ₹392 per equity share
- IPO Open / Close Dates: March 24, 2026 – March 27, 2026
- Lot Size: 38 Shares (Minimum Investment: ₹14,896)
- Issue Size: ~₹408.79 Crores
- Fresh Issue: ₹285 Crores
- Offer for Sale (OFS): Up to 31,57,880 shares (~₹123.79 Crores)
- Registrar: Bigshare Services Private Limited
- Listing Exchange: NSE, BSE
Investors seeking help with registrar for allotment related issues can check our detailed bigshare ipo allotment guide which has step by step details.
What Is The Sai Parenteral's IPO GMP Today?
You can check the GMP of this and other issues at our GMP today page.
Note: The Grey Market Premium (GMP) changes daily based on market demand. It is an unofficial indicator and is not regularised by SEBI, NSE, or BSE. Investors should not rely solely on GMP for investment decisions.
Listing Updates:
| Type | Issue Price | Open | Gain/loss % |
| Lisiting | 392.00 | 400.00 | 2.04 |
What Are The Important Sai Parenteral's IPO Dates & Allotment Schedule?
For investors planning their capital allocation, here is the critical timeline for the issue:
- IPO Open Date: Tuesday, March 24, 2026
- IPO Close Date: Friday, March 27, 2026
- Basis of Allotment Date: Monday, March 30, 2026
- Refund Initiation Date: Wednesday, April 1, 2026
- Credit of Shares: Wednesday, April 1, 2026
- Listing Date: Thursday, April 2, 2026
What Are The Objectives of Sai Parenteral's IPO?
The company proposes to utilise the Net Proceeds from the Fresh Issue towards the following strategic purposes:
- Capacity Expansion & Upgradation: Approximately ₹110.80 Crores is earmarked for expanding and upgrading the existing manufacturing units to meet growing export and CDMO demands.
- New R&D Centre:₹18.02 Crores will be invested to establish a new research and development centre to bolster proprietary formulation capabilities.
- Debt Repayment (General & Acquisition):₹14.30 Crores is allocated for the repayment of specific outstanding debt, and an additional ₹35.64 Crores will be used to repay bridge and term loans associated with the acquisition of Noumed Pharmaceuticals Pty Limited in Australia.
- Working Capital:₹33.00 Crores to meet ongoing working capital requirements.
- General Corporate Purposes: The remaining balance will fund operational contingencies.
How is The Financial Performance of Sai Parenteral's?
The following table summarises the financial performance of the company based on restated consolidated financial statements.
(Figures in ₹ Crores)
| Particulars | Period Ended 30 Sep 25 (6M) | FY Ended 31 Mar 25 | FY Ended 31 Mar 24 | FY Ended 31 Mar 23 |
Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
Profit After Tax (PAT) | 7.76 | 14.45 | 8.42 | 4.38 |
EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
Assets | 376.24 | 272.39 | 268.10 | 133.96 |
Source: RHP
Financial Analysis & Observations:
Total Income:
The company demonstrated a strong growth trajectory, with Total Income rising from ₹97.03 Crores in FY23 to ₹163.74 Crores in FY25. This 68% growth over two years is primarily driven by the aggressive expansion of its CDMO services, which grew at an 80.46% CAGR, and deep penetration into export markets.
Profit After Tax (PAT):
PAT more than tripled from ₹4.38 Crores in FY23 to ₹14.45 Crores in FY25. This exceptional bottom-line expansion underscores the company's ability to capitalise on higher-margin export contracts and value-accretive international acquisitions.
EBITDA:
Operational efficiency is robust, with EBITDA climbing to ₹39.44 Crores in FY25. The EBITDA margin expanded from 18.22% in FY23 to 24.18% in FY25, reflecting better absorption of fixed costs and a lucrative product mix spanning injectables and solid dosages.
Total Borrowing:
Despite being in a capital-intensive sector, total borrowings peaked at ₹118.79 Crores in FY24 before being strategically reduced to ₹76.07 Crores by September 2025. This active deleveraging aligns with the planned use of IPO proceeds to further reduce interest burdens.
Assets:
Total assets surged from ₹133.96 Crores in FY23 to ₹376.24 Crores by September 2025. This massive asset creation is a direct result of strategic acquisitions, including the addition of TGA-approved manufacturing units and the controlling stake in Noumed Pharmaceuticals, Australia.
What Are The P/E Ratio and Peer Comparison?
Based on its Fiscal Year 2025 earnings per share (EPS) of ₹5.43, the IPO is priced at a Price-to-Earnings (P/E) multiple of approximately 72.19x at the upper end of the price band (₹392).
P/E Ratio = ₹392(Price) / ₹5.43 (Earnings Per Share)
P/E Ratio ≈ 72.19x
Peer Comparison Table (FY 2025 Data):
| Company | P/E Ratio | RoNW (%) | EPS (₹) | NAV (₹) |
Sai Parenteral's | ~72.19 | 15.09 | 5.43 | 35.98 |
| Sai Life Sciences | 107.70 | 7.99 | 8.83 | 102.12 |
| Innova Captab | 32.45 | 13.37 | 22.41 | 167.66 |
| Gland Pharma | 44.71 | 7.63 | 42.40 | 555.41 |
| Senores Pharmaceuticals | 64.30 | 7.18 | 16.12 | 176.37 |
Analysis:
Sai Parenteral's is entering the market at a P/E multiple of approximately 72.19x based on its FY25 EPS. While this valuation represents a premium over the industry average P/E of 62.29x and peers like Innova Captab (32.45x), it is notably cheaper than Sai Life Sciences (107.70x).
Crucially, investors should note that Sai Parenteral's has a Return on Net Worth (RoNW) of 15.09%, outperforming all listed peers in the comparison group. This high capital efficiency, combined with its strong CDMO growth and recent international acquisitions, may justify the premium valuation multiple demanded by the promoters.
What is The Industry Outlook For Sai Parenteral?
Growth Potential:
The global pharmaceutical market, particularly the generics and CDMO segments, is experiencing strong tailwinds due to rising healthcare demands, patent cliffs, and the push for cost-effective manufacturing hubs like India.
Market Trends:
There is an increasing trend among multinational pharma companies to outsource development and manufacturing to accredited Indian facilities (WHO-GMP, TGA, PIC/S). Sai Parenteral's robust regulatory approvals position it well to capture this shifting global supply chain.
What Are The Strengths and Risks of Sai Parenteral's IPO?
Strengths:
- Global Accreditations: Manufacturing facilities approved by TGA-Australia and PIC/S create high barriers to entry and open doors to regulated markets.
- CDMO Growth: The CDMO segment provides stable, recurring revenue via long-term contracts, growing at a phenomenal 80%+ CAGR.
- Capital Efficiency: An industry-leading RoNW of 15.09% highlights the management's capability to generate superior returns on shareholder equity.
Risks:
- Product Concentration: Nearly 45% of net revenue in FY25 came from injectable formulations. Any shift in demand or regulatory issue specific to injectables could impact overall profitability.
- Geographic Concentration: Four of the five manufacturing units are located in Hyderabad, exposing the company to regional, political, or natural disruption risks.
- Regulatory Scrutiny: The pharmaceutical sector is highly regulated. Past instances, such as the temporary manufacturing halt directed by the DCA at its subsidiary Revat Laboratories, underscore the continuous compliance risk.
Key Considerations for Investors
This section is neutral and for informational purposes only.
- Valuation vs. Returns: At ~72x P/E, the issue is priced at a premium to the industry average. Investors must weigh this valuation against the company's superior RoNW (15.09%) and strong historical growth.
- Inorganic Growth Strategy: The recent acquisition in Australia (Noumed Pharmaceuticals) is a bold move to capture overseas OTC markets. The successful integration of this acquisition will be critical for future revenue scaling.
- Debt Management: The clear allocation of IPO proceeds toward debt repayment (both general and acquisition-related) is a positive step toward deleveraging the balance sheet and improving future net margins.
Key Takeaways
- IPO Price: ₹392 per share (Upper Band).
- Min Investment: ₹14,896 (38 Shares).
- Valuation: P/E of ~72.19x (Premium to Industry Avg, but highest RoNW).
- Financials: Revenue ₹163 Cr (FY25); PAT ₹14.45 Cr.
- Listing: NSE & BSE on April 2, 2026.
FAQs on Sai Parenteral's IPO
What is Sai Parenteral's IPO GMP today?
The GMP is a dynamic market sentiment indicator. You can check the gmp at our gmp station which is updated regularly.
What is Sai Parenteral's IPO price band?
The price band is fixed at ₹372 to ₹392 per equity share.
What is Sai Parenteral's IPO allotment date?
The allotment status is expected to be finalised on Monday, March 30, 2026.
How to check Sai Parenteral's IPO allotment status?
Investors can check the status on the website of Bigshare Services Private Limited (the Registrar) or via the BSE/NSE IPO allotment portals.
What is Sai Parenteral's IPO listing date?
The shares are tentatively scheduled to list on Thursday, April 2, 2026.
Investment Perspective on Sai Parenteral's IPO
Sai Parenteral's offers a high-quality play in the pharmaceutical CDMO and export space, backed by global accreditations and strong return ratios. While the valuation demands a premium over the industry average, the company's aggressive capacity expansion and strategic international acquisitions present a compelling growth narrative for long-term investors comfortable with the inherent regulatory risks of the pharma sector.
Disclaimer: This article is strictly for educational purposes. Please consult a SEBI-registered investment advisor before making any investment decisions.
